Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics announced the grant of inducement stock options to Mark Sims, its new Chief Commercial Officer, as part of his employment agreement. The options cover 285,000 shares at the current market price and will vest over four years. This grant aims to incentivize leadership as the company advances its clinical-stage immunotherapy progra…